Personalized Treatment Strategies for IBD: Improving Patient Care and Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 15, 2018 to August 15, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Salix, a division of Valeant Pharmaceuticals North America,
and Takeda Pharmaceuticals USA

Inflammatory bowel disease (IBD) is a chronic, systemic autoimmune illness often strikes patients at a young age and the diagnosis of IBD is most commonly based on imaging, a critical role in the initial diagnosis, to assess the portions of the small bowel that is inaccessible to optical endoscopic visualization. This may also include a combination of endoscopy and histopathology. Immediate goals are to control the symptoms, achieve remission, and to help improve a patient’s quality of life, while long-term goals include maintenance of a corticosteroid-free clinical remission, mucosal healing, endoscopic remission, prevention or cure of complications, restoration, and maintenance of proper nutrition. The first pharmacological option are aminosalicylates, which are useful for treating flares and maintaining remission. Antibiotics may also be used to treat bacterial infections that may result from abscesses or fistulas. Corticosteroids are rapid-acting anti-inflammatory agents and are indicated for acute flares of disease only and have no role in the maintenance of remission. Immunomodulators have a slower onset of action and work to reduce patients’ overactive immune system. Finally, the use of biologics, which are proteins that stop certain molecules in the body from causing inflammation in the GI tract, are usually prescribed to those living with moderate to severe cases of IBD who haven’t responded to other types of treatment. Now that there is a better understanding of the pathogenesis of IBD, the development of new therapies targeting the inflammatory pathways is considered a high priority.

Upon completion of this activity, participants will be able to:

  • Analyze the role of emerging therapies with unique mechanisms of action in patients with IBD, including investigational therapies

  • Explore the best practices of diagnosis and classification of patients using laboratory, endoscopic, and imaging studies

  • Identify therapeutic drug monitoring as needed to optimize the management of IBD

  • Discuss the biologic and non-biologic treatments for IBD, including their advantages and limitations

  • Assess strategies to engage patients in self-management opportunities to meet clinical goals and overcome nonadherence

Faculty: Joseph Feuerstein, MD
Attending in Gastroenterology
Beth Israel Deaconess Medical Center
Assistant Professor of Medicine
Harvard Medical School


Dr. Feuerstein has no relevant financial relationships to disclose.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Salix, a division of Valeant Pharmaceuticals North America,
and Takeda Pharmaceuticals USA

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue